samedan logo
 
 
 
spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

Simon Caplan


Editorial

Vanessa Kintu

 

 

Connect with us on Twitter: follow @EBRmagazine
   


 


      Click here to view the digital version of EBR       


ebr
 
 
Featured in this issue
Rare Diseases
The Importance of Patient Advocacy

Jennifer McGrain at Zambon shares her views with EBR surrounding the vital role patient advocates have in helping patients deal with their conditions, particularly those suffering from rare diseases who may struggle to find vital support.

Biopharma post-COVID-19
Medical Communications Transformed

Shairose Ebrahim at integrated medhealth communication (imc)

COVID-19 has led to the drastic transformation of many professional sectors, including those in the medical community. The medical communications sector has been instrumental in making these transformations as smooth as possible.
  Features
The Numerous Challenges of a Rapidly Developing Sector

Carl Niedbala at Founder Shield

Now, more than ever, the biotech industry faces a significant number of risks, including a lengthy pipeline, the complicated process of gaining FDA approval, and higher healthcare costs.

spacer


Published quarterly in
January, April,
July, and October



 

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
News and Press Releases

ERT Expands eCOA Solution for Higher Fidelity CNS Assessments

ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with the leading neuroscience technology company, Cogstate, Ltd. The collaboration enables ERT to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoint measurement to improve safety and efficacy assessment in clinical trials, including capabilities for at-home testing.
More info >>

 
White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement